In September 2025, the U.S. Food and Drug Administration (FDA) approved several new cancer therapies and supportive care ...
Enoby and Xtrenbo are FDA-approved biosimilars for denosumab, providing cost-effective alternatives to Prolia and Xgeva for ...
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...
Earlier this month, the FDA approved Bildyos and Bilprevda (denosumab-nxxp), 2 additional denosumab biosimilars for Prolia ...
Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE: 532523, NSE: ...
Hyderabad: Dr Reddy's Laboratories Ltd., has announced that the European Medicines Agency's (EMA) Committee for Medicinal ...
Original Medicare (Part A and Part B), Part D, and Medicare Advantage typically offer coverage for the osteoporosis drug Prolia. However, individuals must meet certain requirements for Part B coverage ...
EC approves Henlius & Organon’s Bildyos and Bilprevda, biosimilars to Prolia and Xgeva respectively: Shanghai, China Monday, September 22, 2025, 14:00 Hrs [IST] Shanghai Henlius ...
Dr Reddy’s receives positive CHMP opinion from EMA for AVT03, a proposed biosimilar of Prolia and Xgeva: Our Bureau, Bengaluru Tuesday, September 23, 2025, 13:30 Hrs [IST] Dr Re ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback